{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T07:54:51Z","timestamp":1780732491428,"version":"3.54.1"},"reference-count":100,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100011841","name":"Xinxiang Medical University","doi-asserted-by":"publisher","award":["xskjzzd202445"],"award-info":[{"award-number":["xskjzzd202445"]}],"id":[{"id":"10.13039\/501100011841","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011841","name":"Xinxiang Medical University","doi-asserted-by":"publisher","award":["YJSCX202422Y"],"award-info":[{"award-number":["YJSCX202422Y"]}],"id":[{"id":"10.13039\/501100011841","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.critrevonc.2026.105150","type":"journal-article","created":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T00:23:17Z","timestamp":1769214197000},"page":"105150","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["KRAS mutations reshape the immunosuppressive tumor microenvironment in triple-negative breast cancer: A novel perspective"],"prefix":"10.1016","volume":"219","author":[{"given":"Yuanhao","family":"Lv","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyin","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenyu","family":"Di","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiyang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinghua","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiateng","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2026.105150_bib1","doi-asserted-by":"crossref","first-page":"523","DOI":"10.2147\/BCTT.S516125","article-title":"Triple-Negative Breast Cancer on the Rise: Breakthroughs and Beyond","volume":"17","author":"Agelidis","year":"2025","journal-title":"BCTT"},{"key":"10.1016\/j.critrevonc.2026.105150_bib2","doi-asserted-by":"crossref","first-page":"196","DOI":"10.3390\/cells8020196","article-title":"VAS2870 Inhibits Histamine-Induced Calcium Signaling and vWF Secretion in Human Umbilical Vein Endothelial Cells","volume":"8","author":"Avdonin","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.critrevonc.2026.105150_bib3","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1056\/NEJMoa2105281","article-title":"Acquired Resistance to KRASG12C Inhibition in Cancer","volume":"384","author":"Awad","year":"2021","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.critrevonc.2026.105150_bib4","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1038\/s41388-018-0528-1","article-title":"NOX2 inhibition reduces oxidative stress and prolongs survival in murine KRAS-induced myeloproliferative disease","volume":"38","author":"Aydin","year":"2019","journal-title":"Oncogene"},{"key":"10.1016\/j.critrevonc.2026.105150_bib5","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/s41392-023-01705-z","article-title":"Targeting the RAS\/RAF\/MAPK pathway for cancer therapy: from mechanism to clinical studies","volume":"8","author":"Bahar","year":"2023","journal-title":"Sig Transduct. Target Ther."},{"key":"10.1016\/j.critrevonc.2026.105150_bib6","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1093\/jnci\/djz208","article-title":"Unraveling Triple-Negative Breast Cancer Tumor Microenvironment Heterogeneity: Towards an Optimized Treatment Approach","volume":"112","author":"Bareche","year":"2020","journal-title":"JNCI Journal National Cancer Institute"},{"key":"10.1016\/j.critrevonc.2026.105150_bib7","doi-asserted-by":"crossref","first-page":"4097","DOI":"10.1200\/JCO.23.00434","article-title":"Adagrasib in Advanced Solid Tumors Harboring a KRAS G12C Mutation","volume":"41","author":"Bekaii-Saab","year":"2023","journal-title":"JCO"},{"key":"10.1016\/j.critrevonc.2026.105150_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellsig.2023.111008","article-title":"NOX4 alleviates breast cancer cell aggressiveness by co-ordinating mitochondrial turnover through PGC1\u03b1\/Drp1 axis","volume":"115","author":"Bhadane","year":"2024","journal-title":"Cell. Signal."},{"key":"10.1016\/j.critrevonc.2026.105150_bib9","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1186\/s12967-021-03182-w","article-title":"NOX4: a potential therapeutic target for pancreatic cancer and its mechanism","volume":"19","author":"Bi","year":"2021","journal-title":"J. Transl. Med"},{"key":"10.1016\/j.critrevonc.2026.105150_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2023.102795","article-title":"Unlocking the power of NOX2: A comprehensive review on its role in immune regulation","volume":"64","author":"Bode","year":"2023","journal-title":"Redox Biol."},{"key":"10.1016\/j.critrevonc.2026.105150_bib11","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/s41575-019-0245-4","article-title":"Role of oncogenic KRAS in the diagnosis, prognosis and treatment of pancreatic cancer","volume":"17","author":"Buscail","year":"2020","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.critrevonc.2026.105150_bib12","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/s41392-024-01907-z","article-title":"MYC and KRAS cooperation: from historical challenges to therapeutic opportunities in cancer","volume":"9","author":"Casacuberta-Serra","year":"2024","journal-title":"Sig Transduct. Target Ther."},{"key":"10.1016\/j.critrevonc.2026.105150_bib13","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1038\/s41568-021-00435-0","article-title":"The role of ROS in tumour development and progression","volume":"22","author":"Cheung","year":"2022","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105150_bib14","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1089\/ars.2019.7915","article-title":"The NADPH Oxidase Family and Its Inhibitors","volume":"33","author":"Chocry","year":"2020","journal-title":"Antioxid. Redox Signal."},{"key":"10.1016\/j.critrevonc.2026.105150_bib15","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1007\/s00018-012-1009-2","article-title":"NADPH oxidase inhibitors: a decade of discovery from Nox2ds to HTS","volume":"69","author":"Cifuentes-Pagano","year":"2012","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.critrevonc.2026.105150_bib16","doi-asserted-by":"crossref","first-page":"a031849","DOI":"10.1101\/cshperspect.a031849","article-title":"Kras and Tumor Immunity: Friend or Foe?","volume":"8","author":"Cullis","year":"2018","journal-title":"Cold Spring Harb. Perspect. Med"},{"key":"10.1016\/j.critrevonc.2026.105150_bib17","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/S0140-6736(23)00221-0","article-title":"Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial","volume":"401","author":"De Langen","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2026.105150_bib18","doi-asserted-by":"crossref","first-page":"3464","DOI":"10.3390\/ijms25063464","article-title":"Gene Expression and Prognostic Value of NADPH Oxidase Enzymes in Breast Cancer","volume":"25","author":"De Vasconcelos E Souza","year":"2024","journal-title":"IJMS"},{"key":"10.1016\/j.critrevonc.2026.105150_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.104683","article-title":"Tumor microenvironment: Challenges and opportunities in targeting metastasis of triple negative breast cancer","volume":"153","author":"Deepak","year":"2020","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.critrevonc.2026.105150_bib20","doi-asserted-by":"crossref","unstructured":"Dias Carvalho, P., Mendon\u00e7a, S., Martins, F., Oliveira, M.J., Velho, S., 2022. Modulation of fibroblasts phenotype by colorectal cancer cells-secreted factors is mostly independent of oncogenic KRAS. https:\/\/doi.org\/10.1101\/2022.07.05.498793.","DOI":"10.1101\/2022.07.05.498793"},{"key":"10.1016\/j.critrevonc.2026.105150_bib21","doi-asserted-by":"crossref","first-page":"440","DOI":"10.3390\/antiox12020440","article-title":"Targeting M2 Macrophages with a Novel NADPH Oxidase Inhibitor","volume":"12","author":"Dilly","year":"2023","journal-title":"Antioxidants"},{"key":"10.1016\/j.critrevonc.2026.105150_bib22","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1002\/mc.21891","article-title":"Regulation of pancreatic cancer growth by superoxide","volume":"52","author":"Du","year":"2013","journal-title":"Mol. Carcinog."},{"key":"10.1016\/j.critrevonc.2026.105150_bib23","doi-asserted-by":"crossref","DOI":"10.1177\/11795549251331759","article-title":"Potency and Safety of KRAS G12C Inhibitors in Solid Tumors: A Systematic Review","volume":"19","author":"El Zaitouni","year":"2025","journal-title":"Clin. Med Insights Oncol."},{"key":"10.1016\/j.critrevonc.2026.105150_bib24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.52338\/jocbc.2024.4221","article-title":"Oxidative Stress induced by Over-Expressed NADPH Oxidase (NOX) Initiates Breast Cancer, Promotes Metastasis via Epithelial to Mesenchymal Transition (EMT), Remodels Chromatin and Confers Drug Resistance","volume":"8","author":"Fathah","year":"2019","journal-title":"jocbc"},{"key":"10.1016\/j.critrevonc.2026.105150_bib25","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.lungcan.2018.07.013","article-title":"KRAS-Mutant non-small cell lung cancer: From biology to therapy","volume":"124","author":"Ferrer","year":"2018","journal-title":"Lung Cancer"},{"key":"10.1016\/j.critrevonc.2026.105150_bib26","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/s41573-024-00979-4","article-title":"Targeting ROS in cancer: rationale and strategies","volume":"23","author":"Glorieux","year":"2024","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.critrevonc.2026.105150_bib27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2020\/7095902","article-title":"NOX2-Derived Reactive Oxygen Species in Cancer","volume":"2020","author":"Grauers Wiktorin","year":"2020","journal-title":"Oxid. Med. Cell. Longev."},{"key":"10.1016\/j.critrevonc.2026.105150_bib28","first-page":"1883","article-title":"Long-term safety and efficacy of selumetinib in children with neurofibromatosis type 1 on a phase 1\/2 trial for inoperable plexiform neurofibromas","volume":"25","author":"Gross","year":"2023","journal-title":"NeuroOncol."},{"key":"10.1016\/j.critrevonc.2026.105150_bib29","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.2174\/1381612829666230418114520","article-title":"Targeting of SOS1: from SOS1 Activators to Proteolysis Targeting Chimeras","volume":"29","author":"Hamilton","year":"2023","journal-title":"CPD"},{"key":"10.1016\/j.critrevonc.2026.105150_bib30","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1016\/S0140-6736(16)31891-8","article-title":"Breast cancer","volume":"389","author":"Harbeck","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2026.105150_bib31","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1038\/s41388-022-02586-2","article-title":"Triple negative breast tumors contain heterogeneous cancer cells expressing distinct KRAS-dependent collective and disseminative invasion programs","volume":"42","author":"Henriet","year":"2023","journal-title":"Oncogene"},{"key":"10.1016\/j.critrevonc.2026.105150_bib32","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1158\/2159-8290.CD-21-1331","article-title":"Expanding the Reach of Precision Oncology by Drugging All KRAS Mutants","volume":"12","author":"Hofmann","year":"2022","journal-title":"Cancer Discov."},{"key":"10.1016\/j.critrevonc.2026.105150_bib33","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1038\/s41392-021-00780-4","article-title":"KRAS mutation: from undruggable to druggable in cancer","volume":"6","author":"Huang","year":"2021","journal-title":"Sig Transduct. Target Ther."},{"key":"10.1016\/j.critrevonc.2026.105150_bib34","doi-asserted-by":"crossref","first-page":"548","DOI":"10.4048\/jbc.2019.22.e55","article-title":"Prognostic Role of KRAS mRNA Expression in Breast Cancer","volume":"22","author":"Hwang","year":"2019","journal-title":"J. Breast Cancer"},{"key":"10.1016\/j.critrevonc.2026.105150_bib35","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/s13046-025-03394-8","article-title":"Reprogramming the breast tumor immune microenvironment: cold-to-hot transition for enhanced immunotherapy","volume":"44","author":"Imani","year":"2025","journal-title":"J. Exp. Clin. Cancer Res"},{"key":"10.1016\/j.critrevonc.2026.105150_bib36","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1158\/2159-8290.CD-24-0027","article-title":"Translational and Therapeutic Evaluation of RAS-GTP Inhibition by RMC-6236 in RAS-Driven Cancers","volume":"14","author":"Jiang","year":"2024","journal-title":"Cancer Discov."},{"key":"10.1016\/j.critrevonc.2026.105150_bib37","doi-asserted-by":"crossref","first-page":"5322","DOI":"10.3390\/cancers14215322","article-title":"K-RAS Associated Gene-Mutation-Based Algorithm for Prediction of Treatment Response of Patients with Subtypes of Breast Cancer and Especially Triple-Negative Cancer","volume":"14","author":"Johnson","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.critrevonc.2026.105150_bib38","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms14437","article-title":"Mutant Kras- and p16-regulated NOX4 activation overcomes metabolic checkpoints in development of pancreatic ductal adenocarcinoma","volume":"8","author":"Ju","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.critrevonc.2026.105150_bib39","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1038\/s41568-021-00375-9","article-title":"Metabolic networks in mutant KRAS-driven tumours: tissue specificities and the microenvironment","volume":"21","author":"Kerk","year":"2021","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105150_bib40","doi-asserted-by":"crossref","first-page":"9678","DOI":"10.1021\/acs.jmedchem.2c00741","article-title":"Design and Discovery of MRTX0902, a Potent, Selective, Brain-Penetrant, and Orally Bioavailable Inhibitor of the SOS1:KRAS Protein-Protein Interaction","volume":"65","author":"Ketcham","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.critrevonc.2026.105150_bib41","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41591-023-02717-6","article-title":"Sotorasib with panitumumab in chemotherapy-refractory KRASG12C-mutated colorectal cancer: a phase 1b trial","volume":"30","author":"Kuboki","year":"2024","journal-title":"Nat. Med"},{"key":"10.1016\/j.critrevonc.2026.105150_bib42","article-title":"Reactive Oxygen Species: A Key Constituent in Cancer Survival","volume":"13","author":"Kumari","year":"2018","journal-title":"Biomark. \u2370Insights"},{"key":"10.1016\/j.critrevonc.2026.105150_bib43","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s12929-022-00859-2","article-title":"Mitochondrial oxidative stress in the tumor microenvironment and cancer immunoescape: foe or friend?","volume":"29","author":"Kuo","year":"2022","journal-title":"J. Biomed. Sci."},{"key":"10.1016\/j.critrevonc.2026.105150_bib44","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-025-07532-2","article-title":"Binding modes of the KRAS(G12C) inhibitors GDC-6036 and LY3537982 revealed by all atom molecular dynamics simulations","volume":"15","author":"Leini","year":"2025","journal-title":"Sci. Rep."},{"key":"10.1016\/j.critrevonc.2026.105150_bib45","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2022-071674","article-title":"Advances in systemic therapies for triple negative breast cancer","author":"Leon-Ferre","year":"2023","journal-title":"BMJ"},{"key":"10.1016\/j.critrevonc.2026.105150_bib46","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1186\/s12943-021-01463-y","article-title":"Cancer associated-fibroblast-derived exosomes in cancer progression","volume":"20","author":"Li","year":"2021","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105150_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2019.101143","article-title":"NADPH oxidase 2 inhibitors CPP11G and CPP11H attenuate endothelial cell inflammation & vessel dysfunction and restore mouse hind-limb flow","volume":"22","author":"Li","year":"2019","journal-title":"Redox Biol."},{"key":"10.1016\/j.critrevonc.2026.105150_bib48","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/S2213-2600(24)00110-3","article-title":"Garsorasib in patients with KRASG12C-mutated non-small-cell lung cancer in China: an open-label, multicentre, single-arm, phase 2 trial","volume":"12","author":"Li","year":"2024","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.critrevonc.2026.105150_bib49","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1038\/s41419-019-2192-y","article-title":"The impact of oncogenic RAS on redox balance and implications for cancer development","volume":"10","author":"Lim","year":"2019","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.critrevonc.2026.105150_bib50","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1002\/cac2.12327","article-title":"KRAS -G12D mutation drives immune suppression and the primary resistance of anti-PD-1\/PD-L1 immunotherapy in non-small cell lung cancer","volume":"42","author":"Liu","year":"2022","journal-title":"Cancer Commun."},{"key":"10.1016\/j.critrevonc.2026.105150_bib51","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.jacbts.2019.10.004","article-title":"Celastrol Alleviates Aortic Valve Calcification Via Inhibition of NADPH Oxidase 2 in Valvular Interstitial Cells","volume":"5","author":"Liu","year":"2020","journal-title":"JACC Basic Translational Science"},{"key":"10.1016\/j.critrevonc.2026.105150_bib52","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.apsb.2019.03.002","article-title":"Targeting the untargetable KRAS in cancer therapy","volume":"9","author":"Liu","year":"2019","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.critrevonc.2026.105150_bib53","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s12943-023-01850-7","article-title":"Advances in immunotherapy for triple-negative breast cancer","volume":"22","author":"Liu","year":"2023","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105150_bib54","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.canlet.2014.04.001","article-title":"The Warburg effect in tumor progression: Mitochondrial oxidative metabolism as an anti-metastasis mechanism","volume":"356","author":"Lu","year":"2015","journal-title":"Cancer Lett."},{"key":"10.1016\/j.critrevonc.2026.105150_bib55","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1002\/path.5175","article-title":"NOX2 in autoimmunity, tumor growth and metastasis","volume":"247","author":"Martner","year":"2019","journal-title":"J. Pathol."},{"key":"10.1016\/j.critrevonc.2026.105150_bib56","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/s41698-024-00793-6","article-title":"Mechanisms of KRAS inhibitor resistance in KRAS-mutant colorectal cancer harboring Her2 amplification and aberrant KRAS localization","volume":"9","author":"Maruyama","year":"2025","journal-title":"npj Precis. Onc."},{"key":"10.1016\/j.critrevonc.2026.105150_bib57","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1380584","article-title":"KRAS G12C inhibitor combination therapies: current evidence and challenge","volume":"14","author":"Miyashita","year":"2024","journal-title":"Front. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105150_bib58","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.3390\/cells13141221","article-title":"KRAS Mutation Subtypes and Their Association with Other Driver Mutations in Oncogenic Pathways","volume":"13","author":"Mondal","year":"2024","journal-title":"Cells"},{"key":"10.1016\/j.critrevonc.2026.105150_bib59","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.omtn.2018.12.003","article-title":"Activating PTEN Tumor Suppressor Expression with the CRISPR\/dCas9 System","volume":"14","author":"Moses","year":"2019","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.critrevonc.2026.105150_bib60","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s10549-022-06633-0","article-title":"Abundance of reactive oxygen species (ROS) is associated with tumor aggressiveness, immune response and worse survival in breast cancer","volume":"194","author":"Oshi","year":"2022","journal-title":"Breast Cancer Res Treat."},{"key":"10.1016\/j.critrevonc.2026.105150_bib61","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/S1470-2045(11)70044-4","article-title":"A 3\u2032-untranslated region KRAS variant and triple-negative breast cancer: a case-control and genetic analysis","volume":"12","author":"Paranjape","year":"2011","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2026.105150_bib62","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1186\/s13045-022-01375-4","article-title":"Drugging KRAS: current perspectives and state-of-art review","volume":"15","author":"Parikh","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105150_bib63","doi-asserted-by":"crossref","first-page":"398","DOI":"10.3390\/cells11030398","article-title":"KRAS as a Modulator of the Inflammatory Tumor Microenvironment: Therapeutic Implications","volume":"11","author":"Pereira","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.critrevonc.2026.105150_bib64","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.canlet.2016.03.042","article-title":"Reactive oxygen species (ROS) and cancer: Role of antioxidative nutraceuticals","volume":"387","author":"Prasad","year":"2017","journal-title":"Cancer Lett."},{"key":"10.1016\/j.critrevonc.2026.105150_bib65","doi-asserted-by":"crossref","first-page":"26008","DOI":"10.1073\/pnas.2009495117","article-title":"Mechanoactivation of NOX2-generated ROS elicits persistent TRPM8 Ca2+ signals that are inhibited by oncogenic KRas","volume":"117","author":"Pratt","year":"2020","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.critrevonc.2026.105150_bib66","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.3390\/cancers14051321","article-title":"Direct Targeting KRAS Mutation in Non-Small Cell Lung Cancer: Focus on Resistance","volume":"14","author":"Reita","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.critrevonc.2026.105150_bib67","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1186\/s12943-023-01831-w","article-title":"Multifaceted role of redox pattern in the tumor immune microenvironment regarding autophagy and apoptosis","volume":"22","author":"Ren","year":"2023","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105150_bib68","doi-asserted-by":"crossref","first-page":"5306","DOI":"10.3390\/cancers14215306","article-title":"The Predictive and Prognostic Role of RAS-RAF-MEK-ERK Pathway Alterations in Breast Cancer: Revision of the Literature and Comparison with the Analysis of Cancer Genomic Datasets","volume":"14","author":"Rocca","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.critrevonc.2026.105150_bib69","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2023.104228","article-title":"KRAS G12C-mutant driven non-small cell lung cancer (NSCLC)","volume":"195","author":"Rosell","year":"2024","journal-title":"Crit. Rev. Oncol. \/Hematol."},{"key":"10.1016\/j.critrevonc.2026.105150_bib70","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1008743","article-title":"The genomic landscape of metastasis in treatment-na\u00efve breast cancer models","volume":"16","author":"Ross","year":"2020","journal-title":"PLoS Genet"},{"key":"10.1016\/j.critrevonc.2026.105150_bib71","doi-asserted-by":"crossref","DOI":"10.1200\/JCO-25-00040","article-title":"Single-Agent Divarasib in Patients With KRAS G12C -Positive Non-Small Cell Lung Cancer: Long-Term Follow-Up of a Phase I Study","author":"Sacher","year":"2025","journal-title":"JCO JCO"},{"key":"10.1016\/j.critrevonc.2026.105150_bib72","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1038\/s41591-024-02903-0","article-title":"Targeting KRAS in cancer","volume":"30","author":"Singhal","year":"2024","journal-title":"Nat. Med"},{"key":"10.1016\/j.critrevonc.2026.105150_bib73","doi-asserted-by":"crossref","first-page":"2374","DOI":"10.21037\/tlcr-2025-463","article-title":"KRAS and STK11 co-mutations in resectable non-small cell lung cancer: enduring prognostic value and impaired immunotherapy response","volume":"14","author":"Sisca","year":"2025","journal-title":"Transl. Lung Cancer Res"},{"key":"10.1016\/j.critrevonc.2026.105150_bib74","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.1717520115","article-title":"IKK\u03b1 inactivation promotes Kras-initiated lung adenocarcinoma development through disrupting major redox regulatory pathways","volume":"115","author":"Song","year":"2018","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.critrevonc.2026.105150_bib75","doi-asserted-by":"crossref","DOI":"10.1172\/JCI175447","article-title":"Modulation of NOX2 causes obesity-mediated atrial fibrillation","volume":"134","author":"Sridhar","year":"2024","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.critrevonc.2026.105150_bib76","article-title":"KRAS-driven ROS promote malignant transformation","volume":"2","author":"Suh","year":"2015","journal-title":"Mol. Cell. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105150_bib77","doi-asserted-by":"crossref","first-page":"428","DOI":"10.3390\/cancers17030428","article-title":"The Role of KRAS Mutations in Colorectal Cancer: Biological Insights, Clinical Implications, and Future Therapeutic Perspectives","volume":"17","author":"Takeda","year":"2025","journal-title":"Cancers"},{"key":"10.1016\/j.critrevonc.2026.105150_bib78","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1186\/s12943-021-01422-7","article-title":"Oncogenic KRAS blockade therapy: renewed enthusiasm and persistent challenges","volume":"20","author":"Tang","year":"2021","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105150_bib79","unstructured":"Tokumaru, Y., Oshi, M., Katsuta, E., Yan, L., Satyananda, V., Matsuhashi, N., Futamura, M., Akao, Y., Yoshida, K., Takabe, K., n.d. KRAS signaling enriched triple negative breast cancer is associated with favorable tumor immune microenvironment and better survival."},{"key":"10.1016\/j.critrevonc.2026.105150_bib80","doi-asserted-by":"crossref","first-page":"4325","DOI":"10.3390\/ijms21124325","article-title":"Targeting KRAS Mutant Non-Small-Cell Lung Cancer: Past, Present and Future","volume":"21","author":"Uras","year":"2020","journal-title":"IJMS"},{"key":"10.1016\/j.critrevonc.2026.105150_bib81","doi-asserted-by":"crossref","first-page":"890","DOI":"10.3390\/antiox10060890","article-title":"NADPH Oxidases (NOX): An Overview from Discovery, Molecular Mechanisms to Physiology and Pathology","volume":"10","author":"Vermot","year":"2021","journal-title":"Antioxidants"},{"key":"10.1016\/j.critrevonc.2026.105150_bib82","doi-asserted-by":"crossref","first-page":"71","DOI":"10.4103\/jdmimsu.jdmimsu_703_23","article-title":"Detection of KRAS Mutations in Triple-negative Breast Cancers by Polymerase Chain Reaction","volume":"19","author":"Vodithala","year":"2024","journal-title":"J. Datta Meghe Inst. Med. Sci. Univ."},{"key":"10.1016\/j.critrevonc.2026.105150_bib83","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.1021\/acs.jmedchem.1c01688","article-title":"Identification of MRTX1133, a Noncovalent, Potent, and Selective KRASG12D Inhibitor","volume":"65","author":"Wang","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.critrevonc.2026.105150_bib84","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2023.102763","article-title":"NOX2 inhibition stabilizes vulnerable plaques by enhancing macrophage efferocytosis via MertK\/PI3K\/AKT pathway","volume":"64","author":"Wang","year":"2023","journal-title":"Redox Biol."},{"key":"10.1016\/j.critrevonc.2026.105150_bib85","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1158\/1078-0432.CCR-23-2098","article-title":"A Small Molecule with Big Impact: MRTX1133 Targets the KRASG12D Mutation in Pancreatic Cancer","volume":"30","author":"Wei","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105150_bib86","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.3390\/cancers11081191","article-title":"Reactive Oxygen Species in the Tumor Microenvironment: An Overview","volume":"11","author":"Weinberg","year":"2019","journal-title":"Cancers"},{"key":"10.1016\/j.critrevonc.2026.105150_bib87","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1158\/2159-8290.CD-22-0158","article-title":"Discovery, Preclinical Characterization, and Early Clinical Activity of JDQ443, a Structurally Novel, Potent, and Selective Covalent Oral Inhibitor of KRASG12C","volume":"12","author":"Weiss","year":"2022","journal-title":"Cancer Discov."},{"key":"10.1016\/j.critrevonc.2026.105150_bib88","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/s12935-024-03261-0","article-title":"The molecular subtyping and precision medicine in triple-negative breast cancer---based on Fudan TNBC classification","volume":"24","author":"Weng","year":"2024","journal-title":"Cancer Cell Int"},{"key":"10.1016\/j.critrevonc.2026.105150_bib89","article-title":"Small molecular inhibitors for KRAS-mutant cancers","volume":"14","author":"Wu","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105150_bib90","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1366260","article-title":"Mechanisms of resistance to targeted therapy and immunotherapy in non-small cell lung cancer: promising strategies to overcoming challenges","volume":"15","author":"Xiang","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105150_bib91","doi-asserted-by":"crossref","DOI":"10.1096\/fj.202500238RRR","article-title":"NOX Family: Regulators of Reactive Oxygen Species Balance in Tumor Cells","volume":"39","author":"Xiong","year":"2025","journal-title":"FASEB J."},{"key":"10.1016\/j.critrevonc.2026.105150_bib92","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/s41392-024-02108-4","article-title":"Breast cancer: pathogenesis and treatments","volume":"10","author":"Xiong","year":"2025","journal-title":"Sig Transduct. Target Ther."},{"key":"10.1016\/j.critrevonc.2026.105150_bib93","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.116058","article-title":"Unveiling the role of KRAS in tumor immune microenvironment","volume":"171","author":"Xu","year":"2024","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.critrevonc.2026.105150_bib94","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13058-020-01296-5","article-title":"Triple-negative breast cancer molecular subtyping and treatment progress","volume":"22","author":"Yin","year":"2020","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.critrevonc.2026.105150_bib95","doi-asserted-by":"crossref","unstructured":"Yoon, C., Lu, J., Jun, Y., Suh, Y.-S., Kim, B.-J., Till, J., Kim, J.H., Ryeom, S., Yoon, S.S., Keshavjee, S., 2022. KRAS activation in gastric cancer stem-like cells promotes tumor angiogenesis and metastasis. https:\/\/doi.org\/10.21203\/rs.3.rs-2117637\/v1.","DOI":"10.21203\/rs.3.rs-2117637\/v1"},{"key":"10.1016\/j.critrevonc.2026.105150_bib96","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/s41392-025-02315-7","article-title":"Efficacy and safety of IBI351 (fulzerasib) monotherapy in KRASG12C inhibitor-na\u00efve Chinese patients with KRASG12C-mutated metastatic colorectal cancer: a pooled analysis from phase I part of two studies","volume":"10","author":"Yuan","year":"2025","journal-title":"Sig Transduct. Target Ther."},{"key":"10.1016\/j.critrevonc.2026.105150_bib97","article-title":"Current status of KRAS G12C inhibitors in NSCLC and the potential for combination with anti-PD-(L)1 therapy: a systematic review","volume":"16","author":"Zhang","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105150_bib98","doi-asserted-by":"crossref","first-page":"46","DOI":"10.5858\/arpa.2022-0070-RA","article-title":"Molecular Classification of Breast Cancer: Relevance and Challenges","volume":"147","author":"Zhang","year":"2023","journal-title":"Arch. Pathol. Lab. Med."},{"key":"10.1016\/j.critrevonc.2026.105150_bib99","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.7150\/ijbs.88779","article-title":"Impact of KRAS mutation on the tumor microenvironment in colorectal cancer","volume":"20","author":"Zhou","year":"2024","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.critrevonc.2026.105150_bib100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2019\/5921503","article-title":"The Protective Roles of Estrogen Receptor \u03b2 in Renal Calcium Oxalate Crystal Formation via Reducing the Liver Oxalate Biosynthesis and Renal Oxidative Stress-Mediated Cell Injury","volume":"2019","author":"Zhu","year":"2019","journal-title":"Oxid. Med. Cell. Longev."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826000375?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826000375?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T21:38:00Z","timestamp":1778794680000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842826000375"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":100,"alternative-id":["S1040842826000375"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105150","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"KRAS mutations reshape the immunosuppressive tumor microenvironment in triple-negative breast cancer: A novel perspective","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105150","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"105150"}}